Durable clinical benefit from gefitinib plus bevacizumab in a non-small cell lung cancer patient with an acquired C797S mutation following osimertinib treatment: a case report and literature review
This case indicates that the combination of gefitinib and bevacizumab may offer a durable clinical benefit for NSCLC patients who develop osimertinib resistance via the C797S mutation. The observed outcomes warrant further investigation into this dual-blockade strategy, especially given the limited duration of response noted for tyrosine kinase inhibitor (TKI) monotherapy.
Authors
- Yun Dai (ORCID: https://orcid.org/0000-0003-2285-0818)
- Lei Yue (ORCID: https://orcid.org/0000-0002-8753-5686)
- Wenbo Li (ORCID: https://orcid.org/0000-0002-9042-5664)
- Yuan Liu (ORCID: https://orcid.org/0000-0002-2923-3727)
- Xi Li (ORCID: https://orcid.org/0000-0002-9753-6148)
- Meng Dong (ORCID: https://orcid.org/0000-0001-9622-1737)
- Yuping Tan
- Fei Xiong (ORCID: https://orcid.org/0000-0002-3834-9561)
- Bao Weidong
Institutions
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-13
- DOI
- https://doi.org/10.3389/fonc.2025.1673836
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00